Engine Biosciences

9:45 AM - 10:00 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Engine Biosciences is a platform-based drug discovery company at the intersection of computation and high-throughput biological experimentation, leveraging technology from its co-founders, leading professors in systems and synthetic biology at MIT, UCSD, and Mayo Clinic.

Engine has a computational and machine learning platform that is tightly coupled with a patented high-throughput combinatorial gene perturbation platform, CombiGEM, for rapid predictions and validation of new targets, biomarkers, and synthetic lethal interactions, and capabilities to develop drugs directed at novel biology. Engine’s platform has received issued patents and has been published in leading journals like Science, Cell, and Nature Biotechnology.

Engine is currently working in oncology, CNS, and dermatology internally and in Fortune 500 company collaborations. Engine is led by a team of experienced company builders, drug discovery veterans, data scientists and engineers in SF Bay Area and Singapore.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
Multiple oncology programs - validated targets / drug hits
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided